Screener
Rapport Therapeutics, Inc. RAPP Q3 2026 earnings
Reported November 4, 2026 · Before market open
Revenue-Miss by $7.1K
EPS-$0.84Beat by $0.34
Revenue estimate$7.1K
EPS estimate-$1.18
“We continue to deliver on our priorities with strong execution across the portfolio. Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets. We are building on this momentum, with a steady cadence of catalysts ahead. With the additional capital from our recent financing, we are well funded to deliver on the catalysts ahead and remain committed to delivering sustained value for both patients and shareholders.”
Next report
Date not yet announcedValuation & ratios
Versus estimates
Revenue
Q3 2026-Miss by $7.1K
Q1 2026$20.0MBeat by $12.5MDiluted EPS
FAQ
- When did Rapport Therapeutics, Inc. report Q3 2026 earnings?
- Rapport Therapeutics, Inc. (RAPP) reported Q3 2026 earnings on November 4, 2026 before market open.
- What were Rapport Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Rapport Therapeutics, Inc. reported revenue of - and eps of $-0.84 for Q3 2026.
- Did Rapport Therapeutics, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $7.1K by $7.1K. EPS beat the consensus estimate of $-1.18 by $0.34.
- How did Rapport Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 18.3% from $-0.71.
- Where can I find Rapport Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-446202) and the 10-Q periodic report (0001193125-26-446217) directly on SEC EDGAR. The filing index links above go to sec.gov.
